Navigation Links
JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash
Date:3/11/2009

Agreement the Viso Shareholders are considered to be acting jointly or in concert with JLL.

About JLL Partners

JLL Partners, Inc. is a New York-based leading private equity investment firm with approximately $4.0 billion of capital under management. JLL's investment philosophy is to partner with outstanding management teams and invest with them in companies that they can continue to grow into market leaders. JLL has invested in a variety of industries, with special focus on financial services, building products, and healthcare services and medical products. More information on JLL can be found on the website www.jllpartners.com.

About Patheon

Patheon Inc. is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from pre-clinical development to manufacturing of a full array of dosage forms. Patheon's global network of ten manufacturing facilities and six development centers ensures that customer products can be launched with confidence anywhere in the world. More information on Patheon can be found on the website www.patheon.com.

Additional Information

The offer is being made for the securities of a Canadian issuer. The offer is subject to disclosure requirements of Canada. Shareholders should be aware that these requirements are different from those of the United States. Financial information included herein, if any, has been prepared in accordance with Canadian generally accepted accounting principles and thus may not be comparable to financial information reported by United States companies.

This announce
'/>"/>

SOURCE JLL Patheon Holdings, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Exelixis Commences Public Offering of Common Stock
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
5. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
6. Cytopia Commences Phase II Cancer Drug Study
7. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
8. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
9. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
10. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
11. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... M. D. Anderson Cancer Center will hold the ... December 6-7, to bring together internationally recognized breast ... present new clinical discoveries and participate in educational ... management of this rare but deadly disease. , ...
... fibrosis in first 6 months appears most effective, Australian ... It may be possible to control the progression of ... the disease in infants, according to Australian researchers. , ... can start as early as infancy, even though lung ...
... Teenager and His Family , , ... his 13 years, Dustin Monk will have reason to smile this ... ( www.thescooterstore.com ), Dustin will finally have the mobility and independence ... Today, just weeks after Dustin,s father, Danny Monk, contacted The ...
... those denied under current protocols, study says , , FRIDAY, ... who don,t meet criteria used to select transplant patients could ... Italian study. , The Milan criteria specifies that liver cancer ... in diameter, or three or fewer tumors, each no more ...
... Shot , , , ... County is the North Central region,s first state laboratory-confirmed case of ... , "Peak flu season is quickly ... importance of getting vaccinated. It,s the best way to protect ...
... Devices, Inc. (ADI) took part in the ... December 4-5, 2008, in Cambridge, Mass. Analog ... about healthcare market segmentation and trends affecting ... Healthcare Team Technology Director Tom O’Dwyer participated ...
Cached Medicine News:Health News:M. D. Anderson to hold first international conference on inflammatory breast cancer 2Health News:Aggressive Therapy May Stem CF Progression in Infants 2Health News:The SCOOTER Store Donates Power Wheelchair to Texas Teenager With Rare Genetic Disorders 2Health News:The SCOOTER Store Donates Power Wheelchair to Texas Teenager With Rare Genetic Disorders 3Health News:New Criteria Could Expand Number of Liver Transplant Candidates 2Health News:Health Department Reports North Central Region's First Lab-Confirmed Flu Case of the Season 2Health News: Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 2Health News: Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 3Health News: Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems. 4
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
250L...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: